The operations mainly involve phony or illegal versions of Novo Nordisk’s diabetes drug Ozempic and its obesity drug Wegovy as well as Eli Lilly ... on its website and corporate documents ...

Benchmark Gensuite, an industry-leading Environmental, Health, and Safety (EHS) and Sustainability platform provider, today announced the strategic acquisition of Anvl, a globally-deployed, AI-powered ...

The platform is at the center of a legal dispute between Max ... including the NCAA’s Hall of Champions, Eli Lilly and Co., Intel Corp. and Twitter. Anacore was acquired by San Jose, California ...

Eli Lilly is expanding its innovation digs to Beijing, opening two research centers called the Eli Lilly China Medical ...

DBS analyst Nico Chen has maintained their bullish stance on LLY stock, giving a Buy rating yesterday. Nico Chen has given his Buy rating due ...

In a report released today, Steve Scala from TD Cowen maintained a Buy rating on Eli Lilly & Co (LLY – Research Report), with a ...

Insitro has teamed up with Eli Lilly to help power programs ... News of today's deals comes two months after Lilly opened a $700 million R&D center in the Boston Seaport intended to “push ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE ... in productivity and a low labor share of corporate income. She expressed confidence in the labor market's ...

Eli Lilly and Company (NYSE: LLY) today announced the opening of the Lilly Seaport Innovation Center (LSC), a research and development facility in the Boston Seaport dedicated to advancing Lilly's ...

Last week, the Food and Drug Administration declared an end to the shortage of Eli Lilly’s tirzepatide, sold under the brand name Mounjaro for diabetes and Zepbound for obesity. The move was a ...

Machine-learning drug development company Insitro has inked three agreements with Eli Lilly for new medicines for metabolic diseases. But the deal is a little different compared to many recent ...